Key Takeaways

  • Outside-in due diligence rarely catches internal friction; Inflexion runs an operational diagnostic across leadership, finance, and sales only after closing.
  • During the buyout of British skincare maker Medik8, early operational testing revealed direct-to-consumer expansion in the US had far more upside than underwritten, accelerating a capital reallocation that led to an exit to L'Oréal.
  • Inflexion evaluates finance bench strength two to three levels below the CFO, reviewing board pack quality and management information systems to confirm the reporting base can support expansion.
  • Executive evaluations map specific leader competencies directly against underwriting milestones to decide whether to back, supplement, or replace incumbent personnel.
  • The firm formalizes this post-close evaluation through Inflexion's 90-Day Launchpad Process to reprioritize capital and operating focus before initial plans stall.

The Inflexion's 90-Day Launchpad Process

Step 1: Management Competency and Alignment Assessment

Run a full-fledged management assessment across leadership. Compare existing executive skills against the requirements of the underwriting value creation plan to determine whether to support, supplement, or replace talent.

Step 2: Finance and Reporting Infrastructure Diagnostic

Audit the finance organization, including board pack quality, management information (MI) reliability, underlying ERP/reporting systems, and bench strength at the second and third tiers beneath the CFO.

Step 3: Go-to-Market and Sales System Audit

Examine the operational structure of the sales team, sales enablement tools, pipeline tracking, and tech stack systems area by area across the company.

Step 4: Strategic Value Creation Plan Reprioritization

Synthesize diagnostic findings to recalibrate the management team's agenda. Elevate high-ROI, lower-hanging fruit initiatives and allocate resources earlier to high-conviction growth legs based on operational reality.

When This Works (and When It Doesn't)

This diagnostic runs during the first three months after closing, once a sponsor can inspect internal operations that pre-deal diligence cannot reveal. As Flor Kassai put it, “The reality is that you can only really know what you have bought once you are able to lift the lid, and you can only do that once you own the business.” (play from 8:33) Outside-in reviews show market tailwinds and reported earnings, but they rarely expose whether the mid-level finance team can build an accurate board pack or whether sales tools track real pipeline conversion. Hugh MacArthur observed that few sponsors take the step to “actually look at what is it going to take in order to create the value that I've underwritten, and then what types of management or board level capabilities and competencies are required to execute on that.” (play from 10:30)

The framework breaks down when deal teams treat the underwriting investment thesis as sacred dogma. If an investment committee views post-close diagnostic findings as an admission of flawed diligence rather than updated operational data, sponsors double down on low-yield initiatives instead of shifting capital. It also stumbles in carve-outs lacking standalone financial systems, where basic reporting takes six months just to function, leaving little infrastructure for an audit to evaluate.

Why It Matters

Mid-market buyout returns no longer come from cheap leverage or multiple expansion. With debt costs elevated, returns hinge entirely on operational execution speed. Kassai notes that the process often reveals quick wins: “Things that you may have decided to do later, you may decide to bring forward because... they're lower hanging fruit and you can get bigger bang for the buck.” (play from 10:00) Inflexion's reallocation of capital into Medik8's American direct-to-consumer channels shows how early diagnostic data shortens the path to an exit. Sponsors who adjust their value creation plan in month three capture upside; those who wait for annual board reviews to discover operational misalignments find themselves stuck in extended holding periods with stagnant assets.